您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Rivenprost
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Rivenprost
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Rivenprost图片
CAS NO:256382-08-8
包装与价格:
包装价格(元)
100ug电议
500ug电议
1mg电议

产品介绍
Cas No.256382-08-8
别名ONO-4819
化学名4-[[2R-[3R-hydroxy-2-[3S-hydroxy-4-[3-(methoxymethyl)phenyl]-1R-buten-1E-yl]-5-oxocyclopentyl]ethyl]thio]-butanoic acid, methyl ester
Canonical SMILESO=C1[C@H](CCSCCCC(OC)=O)[C@@H](/C=C/[C@@H](O)CC2=CC(COC)=CC=C2)[C@H](O)C1
分子式C24H34O6S
分子量450.6
溶解度30mg/ml in ethanol, or in DMF, 20mg/mL in DMSO
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Prostaglandin E2 activates four distinct G protein-coupled receptors, EP1-4. Rivenprost is a potent and selective agonist for the EP4 receptor (Ki = 0.7, 56, 620, and >10,000 nM for EP4, EP3, EP2, and EP1, respectively). It has been used to promote EP4-mediated bone formation, prevent bone loss related to osteoporosis, drive osteoblast differentiation, and stabilize bone implants.[1][2][3][4][5] Rivenprost has also been used to support wound healing.[6]

Reference:
[1]. Yoshida, K., Oida, H., Kobayashi, T., et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proceedings of the National Academy of Sciences of the United States of America 99(7), 4580-4585 (2002).
[2]. Ninomiya, T., Hosoya, A., Hiraga, T., et al. Prostaglandin E2 receptor EP4-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation. European Journal of Pharmacology 650, 396-402 (2011).
[3]. Ito, M., Nakayama, K., Konaka, A., et al. Effects of a prostaglandin EP4 agonist, ONO-4819, and risedronate on trabecular microstructure and bone strength in mature ovariectomized rats. Bone 39, 453-459 (2006).
[4]. Nakagawa, K., Imai, Y., Ohta, Y., et al. Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation. Bone 41, 543-548 (2007).
[5]. Hayashi, K., Fotovati, A., Abu Ali, S., et al. Effect of a prostaglandin EP4 receptor agonist on early fixation of hydroxyapatite/titanium composite- and titanium-coated rough-surfaced implants in ovariectomized rats. J.Biomed.Mater.Res.A 92(3), 1202-1209 (2010).
[6]. Honma, Y., Arai, I., Hashimoto, Y., et al. Prostaglandin D2 and prostaglandin E2 accelerate the recovery of cutaneous barrier disruption induced by mechanical scratching in mice. European Journal of Pharmacology 518, 56-62 (2005).